SEARCH

SEARCH BY CITATION

References

  • 1
    Azpiroz F & Malagelada J-R. Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology 1987; 92: 93443.
  • 2
    Mearin F, Cucala M, Azpiroz F, Malagelada J-R. The origin of symptoms on the brain–gut axis in functional dyspepsia. Gastroenterology 1991; 101: 9991006.
  • 3
    Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109: 75565.
  • 4
    Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 134652.
  • 5
    Thumshirn M, Camilleri M, Saslow SB, Williams DE, Burton DD, Hanson RB. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 1999; 44: 5564.
  • 6
    Distrutti E, Azpiroz F, Soldevilla A, Malagelada J-R. Gastric wall tension determines perception of gastric distention. Gastroenterology 1999; 116: 103542.
  • 7
    Bruley des Varannes S, Ropert A, Parys V, Chayvialle JA, Roze C, Galmiche JP. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995; 109: 329.
  • 8
    Coulie B, Tack J, Maes B, Geypens B, De Roo M, Janssens J. Sumatriptan a selective 5-HT1 receptor agonist, induces a lag phase in gastric emptying of liquids in humans. Am J Physiol 1997; 272: G9028.
  • 9
    Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharm Ther 1998; 12: 7616.
  • 10
    Gershon MD. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharm Ther 1999; 13: 1530.
  • 11
    Hicks GA, Schindler M, Bland-Ward PA, Lummis S, Humphrey PA. 5-HT3 receptors on spinal primary afferents projecting to the colon of the rat—a peripheral target for alosetron. Gastroenterology 2000; 118: A631A631.
  • 12
    Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 52537.
  • 13
    Gilja OH, Hausken T, Odegaard S, Berstad A. Three-dimensional ultrasonography of the gastric antrum in patients with functional dyspepsia. Scand J Gastroenterol 1996; 31: 84755.
  • 14
    Hanson DP, Robb RA, Aharon S, et al. New software tool kits for comprehensive visualization and analysis of three-dimensional multimodal biomedical images. J Digit Imaging 1997; 10: 22930.
  • 15
    Prather CM, Foley MK, Geisler KL, O'Connor MK, Hanson RB. A novel enhanced scintigraphic image analysis of gastric motor physiology using ANALYZE™. Gastroenterology 1996; 110: A739A739.
  • 16
    O'Connor MK, O'Connell PR, Keane FB, Byrne PJ, Hennessy TPJ. The relationship between technetium 99mpertechnetate gastric scanning and gastric contents. Br J Radiol 1983; 56: 81722.
  • 17
    Prather CM, Camilleri M, O'Connor MK, et al. Labeling gastric wall facilitates accurate detection of antral wall motion in fasting and fed states. Gastroenterology 1995; 108: A671A671.
  • 18
    Tosetti C, Salvioli B, Stanghellini V, Cogliandro L, Cogliandro R, Marra MG. Reproducibility of a water load test in healthy subjects and symptom profile compared to patients with functional dyspepsia. Gastroenterology 1999; 116: A336A336.
  • 19
    Boeckstaens GE, Hirsch DP, Berkhout B, Tytgat GN. Is a drink test a valuable tool to study proximal stomach function? Gastroenterology 1999; 116: A960A960.
  • 20
    Harper PV, Andros G, Lanthrop K. Preliminary observations on the use of six-hour 99mTc as a tracer in biology and medicine. Semiannual Report of the Argonne Cancer Research Hospital 1962; 18: 7687.
  • 21
    Williams JG. Pertechnetate and the stomach—a continuing story. J Nucl Med 1983; 24: 6338.
  • 22
    Kuiken SD, Samsom M, Camilleri M, et al. Development of a test to measure gastric accommodation in humans. Am J Physiol 1999; 277: G121721.
  • 23
    Jack CR, Peterson RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical ageing and Alzheimer’s disease. Neurology 1998; 51: 9939.
  • 24
    Bouras EP, Camilleri M, Burton D, Thomforde GM, Brinkmann BH. SPECT test to measure gastric accommodation validated with simultaneous barostat measurement. Gastroenterology 2001; 120: A97A97.
  • 25
    Sigma Stat® Statistical Software. Version 2.0 for Windows® 95, NT and 3.1. Chicago, IL: SPSS Inc., 1997.
  • 26
    Feinle C & Read NW. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 271: G5917.
  • 27
    Wilmer A, Coulie B, Tack J, Janssens J. Effect of the 5-HT3 receptor antagonist, ondansetron, on gastric accommodation and on perception of gastric distension after a meal. Gastroenterology 1996; 110: A781A781.
  • 28
    Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 4037.
  • 29
    Bjornsson ES, Chey WD, Ladabaum U, et al. Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex. Am J Physiol 1998; 275: G498505.
  • 30
    Miura M, Lawson DC, Clary EM, Mangel AW, Pappas TN. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 204.
  • 31
    Heath MR, Drossman DA, Whitehead WE, et al. Alosetron does not improve anxiety in female IBS patients. Gastroenterology 2000; 118: A616A616.
  • 32
    Kim D-Y, Delgado-Aros S, Camilleri M, et al. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol in press.
  • 33
    Samsom M, Verhagen MA, Van Berge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116: 51520.
  • 34
    Cubeddu LX. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 1996; 53: 1825.
  • 35
    Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 47480.DOI: 10.1136/gut.46.4.474
  • 36
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT3-receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.DOI: 10.1046/j.1365-2036.1999.00610.x
  • 37
    Akkermans LM, Vos A, Hoekstra A, Roelofs JM, Horowitz M. Effect of ICS 205–930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 1988; 29: 124952.